Lopaciuk study - description and results

Trial-Results center
Clinical trial results database		Feedback Home

This trial is included in the following systematic reviews and meta-analyses:

venous thrombosis - antithrombotics - all type of patients

venous thrombosis - heparin (UFH or LMWH) - all type of patients

venous thrombosis - UFH - all type of patients

Related trials

Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin

RE-COVER, 2009 - dabigatran vs vitamin K antagonists

Romera, 2009 - Tinzaparin vs acenocoumarol

Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin

Botticelli DVT, 2008 - apixaban vs heparin/VKA

Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA

VanGogh DVT, 2007 - idraparinux vs heparin/VKA

VanGogh PE, 2007 - idraparinux vs heparin/VKA

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Fiessinger , 2005 - ximelagatran vs vitamin K antagonists

Chong, 2005 - LMWH at home vs UFH in hospital

Kearon, 2004 - 4 months vs 3 months

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

MATISSE, 2004 - fondaparinux vs enoxaparin

Lee, 2003 - Dalteparin vs warfarin

Agnelli, 2003 - 6-12 months vs 3 months

Kakkar, 2003 - Bemiparin vs warfarin

Deitcher, 2003 - Enoxaparin vs warfarin

MATISSE PE, 2003 - fondaparinux vs heparin/VKA

Hull, 2002 - Tinzaparin vs warfarin

Meyer, 2002 - Enoxaparin vs warfarin

Agnelli, 2001 - 12 months vs 3 months

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Lopez-Beret, 2001 - Nadroparin vs acenocoumarol

Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin

See also:

All venous thrombosis clinical trials

Lopaciuk study, 3000

Treatments

Studied treatment	subcutaneous sodic heparin 34 400 U daily (mean)
Control treatment	intravenous sodic heparin 37 000 U daily (mean)

Patients

Method and design

Randomized effectives

48 / 46 (studied vs. control)

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Recurrent thromboembolic event

2 / 48
7 / 46
0,27 [0,06;1,25]

Major bleeding

2 / 48
1 / 46
classic 1,92 [0,18;20,43] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial
Recurrent thromboembolic event	2 / 48 (4,2%)	7 / 46 (15,2%)	0,27	[0,06;1,25]
Major bleeding	2 / 48 (4,2%)	1 / 46 (2,2%)	1,92	[0,18;20,43]
The primary endpoint (if exists) appears in blod characters

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
Recurrent thromboembolic event	4,17%	15,22%	-110,5‰
Major bleeding	4,17%	2,17%	2,0%

Reference(s)

Trials register #

NA

(c) 2004-2010 TrialResults-center - All Rights Reserved

Tweet this | notify a friend